UK markets open in 6 hours

Inhibikase Therapeutics, Inc. (IKT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.1300-0.0300 (-1.39%)
At close: 04:00PM EDT
Show:
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
0
0
0
0
0
Operating expenses
Research development
12,371
13,618
12,035
11,359
893.802
Selling general and administrative
6,526
6,732
6,217
6,508
2,623
Total operating expenses
18,835
20,090
18,129
14,766
2,818
Operating income or loss
-18,835
-20,090
-18,129
-14,766
-2,818
Interest expense
0.163
-
-
19.923
29.402
Income before tax
-18,817
-19,029
-18,054
-14,786
-2,848
Income from continuing operations
-18,817
-19,029
-18,054
-14,786
-2,848
Net income
-18,817
-19,029
-18,054
-14,786
-2,848
Net income available to common shareholders
-18,817
-19,029
-18,054
-14,786
-2,848
Basic EPS
-3.99
-
-4.28
-4.86
-2.10
Diluted EPS
-3.99
-
-4.28
-4.86
-2.10
Basic average shares
4,830
-
4,223
3,035
1,369
Diluted average shares
4,830
-
4,223
3,035
1,369